Shares in Novartis (NYSE:NVS) rose today after the pharmaceutical company met expectations on Wall Street with its second quarter results.
The company posted profits of $1.98 billion, or 84¢ per share, on sales of $12.24 billion for the 3 months ended June 30, for bottom-line growth of 9% on sales loss of -2% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
The post Novartis sales down -2% but ahead of estimates in Q2 appeared first on MassDevice.